News articles about Cidara Therapeutics (NASDAQ:CDTX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cidara Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.0128871576673 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of NASDAQ:CDTX opened at $4.00 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.43 and a quick ratio of 6.43. The stock has a market cap of $83.08, a price-to-earnings ratio of -1.26 and a beta of 1.70. Cidara Therapeutics has a twelve month low of $4.00 and a twelve month high of $8.80.
Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.05. analysts predict that Cidara Therapeutics will post -2.6 EPS for the current fiscal year.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.